Loading stock data…
Tarsus Pharmaceuticals, Inc. (TARS)
$87.22-3.56 (-3.92%)
Market ClosedLast close Sep 8
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $87.22 with a market capitalization of $4.0B. Wall Street consensus targets $94.00 (8 analysts), implying a +7.8% move over the next 12 months. The stock is currently near its 52-week high of $91.53, remaining 26.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $173.91M↑ | $162.05M↑ | $151.67M↑ | $118.70M↑ | $102.66M |
| Gross Profit | $161.80M↑ | $152.66M↑ | $140.74M↑ | $110.39M↑ | $96.42M |
| Operating Income | -$19.91M↓ | -$6.12M↑ | -$7.98M↑ | -$14.53M↑ | -$22.18M |
| Net Income | -$18.55M↓ | -$6.97M↑ | -$8.37M↑ | -$12.59M↑ | -$20.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.95B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.40%
Volume
Today's trading volume
1.81M
Recent News
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap side. Recent news around acquisitions and pipeline expansion adds another layer for investors trying to judge whether the current price fairly reflects the fundamentals. Over the past 3 years the share price has returned about 3.2x, which puts extra focus on whether that move is grounded in underlying value. The acquisition of Alkeus Pharmaceuticals and...
Tarsus (TARS) Q2 2026 Earnings Call Transcript
XDEMVY sales hit $173.9M with 69% growth as Tarsus expands into retinal diseases.
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline.
Tarsus joins Stargardt race to market with $800m Alkeus takeover
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.